Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Triptan nonresponder studies: implications for clinical practice.

David W Dodick1

  • 1Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.

Headache
|February 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of a central CGRP circuit for trigeminal V1-mediated migraine-like pain in mice.

Brain : a journal of neurology·2026
Same author

Sexually dimorphic mediation of experimental post-traumatic headache by orexin receptor signaling.

Pain·2026
Same author

Imaging the later-life white matter pathologies of repetitive head impacts: A novel pattern revealed through T2 FLAIR MRI.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Factors associated with subjective cognitive complaints in former American football players.

Journal of the International Neuropsychological Society : JINS·2026
Same author

Inflammation, Limbic White Matter Microstructure, and Clinical Symptoms in Retired American Football Players With Repetitive Head Impacts.

Neurology·2026
Same author

Integrating gepants into clinical practice for the acute treatment of migraine.

Headache·2026
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
Same journal

American Headache Society 68th Annual Scientific Meeting June 4-7, 2026, Orlando, Florida.

Headache·2026
Same journal

In Memoriam-Doctor J. Keith Campbell.

Headache·2026
Same journal

Hypothalamus as a conductor of the migraine prodrome: A narrative review.

Headache·2026
Same journal

New academic year in Headache.

Headache·2026
Same journal

Essential readings in headache medicine: Top 10 educational articles from 2025.

Headache·2026
See all related articles

Approximately 30% of patients do not respond to a specific triptan migraine medication. Switching to an alternative triptan can provide significant pain relief for these non-responders.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Oral triptans offer migraine pain relief, with a 2-hour response rate around 70% in clinical trials.
  • A significant portion of patients (approximately 30%) exhibit non-response to a particular triptan.
  • Factors contributing to triptan non-response include absorption issues, late administration, inadequate dosage, and individual variability.

Purpose of the Study:

  • To evaluate the efficacy of alternative triptans in patients who are poor responders to initial triptan therapy.
  • To highlight the clinical observation that switching triptans can benefit non-responders.

Main Methods:

  • Review of recent clinical trial data assessing alternative triptan efficacy.
  • Analysis of pain relief rates at 2 hours post-administration for various triptans in non-responder populations.

Related Experiment Videos

Main Results:

  • Patients with poor response to sumatriptan showed 2-hour pain relief rates ranging from 25% to 81% with alternative triptans.
  • Alternative triptans studied include naratriptan, almotriptan, eletriptan, zolmitriptan, and rizatriptan.

Conclusions:

  • Patients experiencing poor response to one triptan may benefit from switching to a different triptan.
  • Physicians should actively assess acute migraine therapy response and consider alternative treatments for non-responders.
  • Clinical questionnaires can aid in identifying patients who would benefit from a change in acute migraine therapy.